Labcorp Launches At-Home Collection Device for Diabetes Risk Testing

Labcorp has developed and is now introducing a new and convenient way for millions of individuals to determine whether they are at risk for developing diabetes. The company’s at-home collection kit—available through Labcorp OnDemand—that measures hemoglobin A1c (HbA1c) from a small blood sample.
 
Labcorp is the only commercial laboratory to provide HbA1c testing using a new, cutting-edge collection device from Weavr Health, a diagnostics company that provides remote biofluid collection devices to extend access to health and wellness testing. In addition, Labcorp is the first and only laboratory to receive approval from the New York State Clinical Laboratory Evaluation Program for testing using the Weavr Velvet blood collection device. This allows for the Labcorp OnDemand Diabetes Risk test to be available nationwide.
 
“Diabetes is a serious disease affecting millions of people in the United States,” said Dr. Brian Caveney, chief medical officer and president, Labcorp Diagnostics. “Our Labcorp OnDemand Diabetes Risk Test at-home collection kit now makes it easier for consumers to understand their diabetes risk and health status using an innovative and approved collection device. This test offers a convenient way for more people to manage their health and stay informed, so they can seek treatment that may lead to better health outcomes.”
 
One of the primary ways to screen for diabetes and prediabetes and monitor the quality of treatment is through a HbA1c test. According to the U.S. Centers for Disease Control and Prevention, 96 million adults have prediabetes in the United States and eight in 10 of them are not aware they have it. More than 37 million people are living with diabetes, and one in five go undiagnosed.
 
The Labcorp OnDemand Diabetes Risk test uses a dried blood technology to give a snapshot of the body’s average blood sugar levels over time. With a prick of the finger and a few drops of blood, consumers can be empowered to proactively monitor their health status on a regular basis from the comfort of their home.
 
The Weavr Velvet device separates plasma and red blood cells, which allows a more in-depth, complex analysis of the sample. It is easy to use and was designed to enclose the sample to keep it contained, safe and stable for transport and testing. After collection, the device is returned to Labcorp via a prepaid FedEx envelope.
 
According to a recent study published by Clinical Chemistry, results from samples collected via the Weavr Velvet device are more than 97% accurate when compared to results from a traditional blood draw. Through an equity investment made by Labcorp, the device was co-developed for HbA1c by the two companies with Weavr remaining the device owner.
 
“Through our collaboration with Labcorp, we are able to bring safe, efficient testing to doorsteps across the country,” Weavr Health CEO Linh Hoang said. “Our goal is to create innovative testing solutions so that people in all communities have access to life-saving diagnostics and feel empowered to take control of their health.”
 
Labcorp is a global life sciences company that generated $16 billion in FY21 revenue. 
 
Weavr Health provides remote biofluid collection devices that can be delivered directly to individuals to extend diagnostic or wellness testing to more people.